Why the study?
Duodenal-jejunal bypass sleeve treatment induces clinically significant weight loss, but its mechanisms of action and the durability of weight loss and metabolic improvements were poorly understood.
Does duodenal-jejunal bypass sleeve (DJBS) implantation improve weight loss and metabolic outcomes in subjects with severe obesity and type 2 diabetes?
Does duodenal-jejunal bypass sleeve (DJBS) implantation improve weight loss and metabolic outcomes in subjects with severe obesity and type 2 diabetes?
DJBS treatment induces substantial weight loss driven by reduced caloric intake linked to augmented upper gastrointestinal symptoms, without altering fat absorption.
DJBS mechanisms in severe obesity and T2D remain hypothesis-generating; larger prospective studies needed before practice implications.
BACKGROUND: Treatment with a duodenal-jejunal bypass sleeve (DJBS) induces clinically significant weight loss, but little is known about the mechanisms of action of this device. AIM: The aim of this study was to characterize the mechanisms of action of the DJBS and determine the durability of weight loss and metabolic improvements. MATERIALS AND METHODS: We studied a cohort of 19 subjects with severe obesity and type 2 diabetes (baseline body mass index: 43.7±5.3 kg/m). Anthropometry, body composition, blood pressure, biochemical measures, and dietary intake were monitored for 48 weeks after DJBS implantation, and then for 1 year after device removal. Gastric emptying and triglyceride absorption were measured at baseline, 8 weeks after implant, and within 3 weeks of device explant. Visceral sensory function was assessed at baseline, 4 weeks after implant, and within 3 weeks after explant. RESULTS: Significant weight loss (P<0.01) occurred following DJBS placement, with a mean weight reduction of 17.0±6.5% at 48 weeks. The symptom burden following a standardized nutrient challenge was increased after DJBS implantation (P<0.05), returning to baseline after DJBS removal. Neither gastric emptying nor triglyceride absorption changed with the device in situ. A significant reduction in energy intake was observed [baseline: 7703±2978 kJ (1841±712 kcal), 24 weeks: 4824±2259 kJ (1153±540 kcal), and 48 weeks: 4474±1468 kJ (1069±351 kcal)]. After 1 year, anthropometry remained significantly improved, but there was no durable impact on metabolic outcomes. CONCLUSIONS: DJBS treatment resulted in substantial weight loss. Weight loss is related to reduced caloric intake, which seems linked to an augmented upper gastrointestinal symptom response, but not altered fat absorption.
No takes yet. Share an insight, caveat, or question.
McMaster et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: